Gene Therapy for Fanconi Anemia Complementation Group A

STATUS

Recruiting
participants needed

5
sponsor

Rocket Pharmaceuticals Inc.

Updated on 19 February 2024

See if I qualify

Summary

Show definitions

The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.

Description

This is a pediatric open-label Phase II clinical trial to assess the efficacy of a hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with FA-A.

Enriched CD34+ hematopoietic stem cells will be transduced ex vivo with the therapeutic lentiviral vector and infused via intravenous infusion following transduction without any prior conditioning.

Details

Condition	Fanconi Anemia Complementation Group A
Age	1years - 100years
Treatment	RP-L102
Clinical Study Identifier	NCT04248439
Sponsor	Rocket Pharmaceuticals Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Fanconi anemia as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
	Patients of the complementation group FA-A
	Minimum age: 1 year and a minimum weight of 8 kg
	At least 30 CD34+ cells/L are determined in one bone marrow (BM) aspiration within 3 months prior to CD34+ cell collection OR (see subsequent criterion)
	If the number of CD34+ cells/ L in BM is in the range of 10-29, peripheral blood (PB) parameters should meet two of the three following criteria
	Hemoglobin: 11g/dL
	Neutrophils: 900 cells/L
	Platelets: 60,000 cells/L
	Provide informed consent in accordance with current legislation
	Women of childbearing age must have a negative urine pregnancy test at the baseline visit, and accept the use of an effective contraception method during participation in the trial
Exclusion Criteria
	Subjects with an available and medically eligible HLA-identical sibling donor
	Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the subject commences the stem cell mobilization/collection procedures of the clinical trial
	Subjects with somatic mosaicism associated with stable or improved counts in all PB cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease (1 NCI CTCAE grade) in at least one blood lineage over time must be documented to enable eligibility, as should <5% resistance of bone marrow colony forming cells (CFCs) to 10nM MMC; whenever possible potential mosaicism should also be evaluated by gene sequencing of MMC-resistant CFCs)
	Lansky performance status 60%
	Any concomitant disease or condition that, in the opinion of the Principal Investigator, renders the subject unfit to participate in the study
	Pre-existing sensory or motor impairment grade 2 according to the criteria of the NCI
	Pregnant or breastfeeding women
	Hepatic dysfunction as defined by either
	Bilirubin >3.0 the upper limit of normal (ULN) or
	Alanine aminotransferase (ALT) > 5.0 ULN or
	Aspartate aminotransferase (AST) > 5.0 ULN
	For subjects with bilirubin, ALT or AST above ULN, a workup to identify the
	etiology of liver abnormality should be conducted prior to confirmation of
	eligibility as stipulated in exclusion criterion 5, including evaluation of
	viral hepatitis, iron overload, drug injury or other causes
	\. Renal dysfunction requiring either hemodialysis or peritoneal dialysis
	\. Pulmonary dysfunction as defined by either
	Need for supplemental oxygen during the prior 2 weeks in absence of acute infection or
	Oxygen saturation by pulse oximetry <90%. 11\. Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years. 12\. Subject is receiving androgens (i.e. danazol, oxymetholone). 13\. Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Gene Therapy for Fanconi Anemia Complementation Group A

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Gene Therapy for Fanconi Anemia Complementation Group A

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note